Linked Life Data

6460831

Source:http://linkedlifedata.com/resource/pubmed/id/6460831

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1982-5-21
pubmed:abstractText
On the basis of preceding studies showing that tumor-induced, T cell-mediated immunosuppression serves as an obstacle to adoptive immunotherapy of the Meth A fibrosarcoma, it was predicted that cyclophosphamide treatment of tumor bearers would remove this obstacle and allow passively transferred immune T cells to cause tumor regression. It was found that infusion of immune spleen cells alone had no effect on tumor growth, and cyclophosphamide alone caused a temporary halt in tumor progression. In contrast, combination therapy consisting of intravenous injection of 100 mg/kg of cyclophosphamide followed 1 h later by intravenous infusion of tumor-immune spleen cells caused small, as well as large tumors, to completely and permanently regress. Tumor regression caused by combination therapy was completely inhibited by intravenous infusion of splenic T cells from donors with established tumors, but not by spleen cells from normal donors. These suppressor T cells were eliminated from the spleen by treating the tumor-bearing donors with 100 mg/kg of cyclophosphamide. Immune T cells, in contrast, were resistant to this dose of cyclophosphamide. These results show that failure of intravenously-infused, tumor-sensitized T cells to cause regression of the Meth A fibrosarcoma growing in its syngeneic or semi-syngeneic host is caused by the presence of a tumor-induced population of cyclophosphamide-sensitive suppressor T cells.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-219129, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-299883, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-326003, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-5014716, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-6445398, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-6457075, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-6788892, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-6974214, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-6974215, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-6974221, http://linkedlifedata.com/resource/pubmed/commentcorrection/6460831-87487
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-1007
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
155
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1063-74
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.